All In Biotech

Drug Trial Radar · NCT05891249

A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

A Phase 4 Study to Evaluate Safety and Effectiveness of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Ring Sideroblasts Who Require Red Blood Cell Transfusions in Participants Who Have Had Unsatisfactory Response to or Are Ineligible to Erythropoietin Based Therapy and in Participants With Transfusion Dependent Anemia Due to Beta-Thalassemia

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Jun 5, 2023

Primary completion

Dec 16, 2028

Study completion Dec 16, 2028

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and effectiveness of luspatercept in participants who require regular blood cell transfusions due to b-thalassemia and myelodysplastic syndromes in India

Conditions

  • Anemia

Interventions

  • LuspaterceptBiological

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. β-Thal Cohort: Number of participants with treatment-related adverse events (AEs) of grade 3 or higherTime frame: Up to 57 weeks
  2. MDS-Ring Sideroblasts (RS) Cohort: Number of participants with treatment-related AEs of grade 3 or higherTime frame: Up to 54 weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0005

    Assam, India

  • Local Institution - 0003

    Bangalore, India

  • Local Institution - 0004

    Chandigarh, India

  • Local Institution - 0010

    Delhi, India

  • Local Institution - 0006

    Hyderabad, India

  • Local Institution - 0008

    Mumbai, India

  • Local Institution - 0002

    Ahmedabad, Gujarat, India

  • Local Institution - 0001

    New Delhi, National Capital Territory of Delhi, India

  • Local Institution - 0007

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.